Bone complications in multiple myeloma

James R. Berenson, Lakshmi Rajdev, Michael Broder

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Multiple myeloma is the malignant proliferation of plasma cells involving more than 10% of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ;, pamidronate (Aredia®; Novartis Pharmaceuticals Corp; East Hanover, NJ; and zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp; East Hanover, NJ; in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.

Original languageEnglish (US)
Pages (from-to)1082-1085
Number of pages4
JournalCancer Biology and Therapy
Issue number9
StatePublished - Sep 2006
Externally publishedYes


  • Bisphosphonates
  • Bone
  • Multiple myeloma
  • Sequelae

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Bone complications in multiple myeloma'. Together they form a unique fingerprint.

Cite this